Úskalí dávkování azathioprinu a cyklosporinu v terapii myastenie
| Title in English | Challenges of ciciosporin and azathioprin dosage for myasthemia gravis |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Neurologie pro praxi |
| MU Faculty or unit | |
| Citation | |
| Field | Neurology, neurosurgery, neurosciences |
| Keywords | azathioprin; ciciosporin; cyclosporin; neoral; therapeutic drug monitoring |
| Description | Azathioprin (Imuran) and ciciosporin (Sandimmun Neoral, Equoral) are among the most widely used immunosuppressive drugs for myasthenia gravis. They are very efficient and help to improve patient's quality of life. However, such therapy has some risks. At least part of the risks can be avoided by managing the right dose, which requires certain experience. The aim of this article is a review of their side effects, metabolic pathways and interactions, therapeutic drug monitoring and some dosage recommendations. |